"New drugs: kids come first": children should be included in trials of new biological treatments.
Inflamm Bowel Dis
; 13(9): 1165-9; discussion 1176-7, 2007 Sep.
Article
in En
| MEDLINE
| ID: mdl-17455208
ABSTRACT
The advent of biological therapies has dramatically revolutionized the treatment options for refractory inflammatory bowel disease (IBD). Of all the biologics evaluated to date, infliximab, an anti-tumor necrosis factor-alpha monoclonal chimeric antibody, has been shown to be an extremely potent drug for acute and maintenance treatment of both adult and pediatric patients with severe IBD, especially in those with Crohn's disease, whereas other biological agents are undergoing evaluation in several clinical trials. Although infliximab has preferentially been used as rescue therapy for IBD patients refractory to traditional drugs, clinical and immunological arguments seem to indicate that the biological agents are an advantageous treatment for children with IBD when given early in the course of the disease. This, however, requires multicenter randomized controlled trials to prove.
Search on Google
Database:
MEDLINE
Main subject:
Research Design
/
Biological Therapy
/
Inflammatory Bowel Diseases
/
Crohn Disease
Type of study:
Clinical_trials
Limits:
Adult
/
Child
/
Humans
Language:
En
Year:
2007
Type:
Article